Severe lactic acidosis associated with linezolid use in a patient with the mitochondrial DNA A2706G polymorphism

Pharmacotherapy

Volumn 27, Issue 5, 2007, Pages 771-774

  Carson, John ^a   Cerda, Jorge ^a   Chae, Jong Hee ^b   Hirano, Michio ^b   Maggiore, Peter ^a  

^a St Peter's Hospital Albany   (United States)

^b Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

A2706G polymorphism; Adverse drug reaction; Hyperlactatemia; Lactic acidosis; Linezolid; Mitochondria

Indexed keywords

ATOVAQUONE; CARNITINE; CLARITHROMYCIN; COTRIMOXAZOLE; EFAVIRENZ; EMTRICITABINE; ERYTHROPOIETIN; ETHAMBUTOL; FOLIC ACID; FOLINIC ACID; ISONIAZID; LACTIC ACID; LAMIVUDINE; LINEZOLID; LOPINAVIR PLUS RITONAVIR; MITOCHONDRIAL DNA; MOXIFLOXACIN; PYRIDOXINE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RIBOFLAVIN; RIFABUTIN; SULFADIAZINE; TENOFOVIR; THIAMINE; UBIDECARENONE; VALACICLOVIR; ZIDOVUDINE;

ABDOMINAL PAIN; ADD ON THERAPY; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CASE REPORT; CENTRAL NERVOUS SYSTEM INFECTION; DIARRHEA; DNA POLYMORPHISM; DRUG WITHDRAWAL; FEMALE; HERPES SIMPLEX; HUMAN; LACTIC ACIDOSIS; MYCOBACTERIUM INTRACELLULARE AVIUM; PANCREATITIS; SHOCK; TOXOPLASMOSIS;

ACETAMIDES; ACIDOSIS, LACTIC; ADULT; ANTI-INFECTIVE AGENTS; DNA, MITOCHONDRIAL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; OXAZOLIDINONES; POLYMORPHISM, GENETIC;

EID: 34247881873     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.5.771     Document Type: Article

References (21)

1. Colca JR, McDonald WG, Waldon DJ, et al. Cross-linking in the living cell locates the site of action of oxazolidinone antibiotics. J Biol Chem 2003;278:21972-9.
2. McKinley SH, Foroozan R. Optic neuropathy associated with linezolid treatment. J Neuroophthalmol 2005;25:18-21.
3. Lee E, Burger S, Shah J, et al. Linezolid-associated toxic optic neuropathy: a report of two cases. Clin Infect Dis 2003;37:1389-91.
4. Rucker JC, Hamilton SR, Bardenstein D, Isada CM, Lee MS. Linezolid-associated toxic optic neuropathy. Neurology 2006;66:595-8.
5. Rho JP, Sia IG, Crum BA, Dekutoski MB, Trousdale RT. Linezolid-associated peripheral neuropathy. Mayo Clin Proc 2004;79:927-30.
6. Soriano A, Miro O, Mensa J. Mitochondrial toxicity associated with linezolid. N Engl J Med 2005;353:2305-6.
7. Apodaca AA, Rakita RM. Linezolid-induced lactic acidosis. N Engl J Med 2003;348:86-7.
8. Palenzuela L, Hahn NM, Nelson RP, et al. Does linezolid cause lactic acidosis by inhibiting mitochondrial protein synthesis [online exclusive article]? Clin Infect Dis 2005;40:e113-16. Available from www.journals.uchicago. edu/CID/journal/issues/v40n12/35321/35321.web.pdf.
9. De Vriese AS, Van Coster R, Smet J, et al. Linezolid-induced inhibition of mitochondrial protein synthesis. Clin Infect Dis 2006;42:1111-17.
10. Nagiec EE, Wu L, Swaney SM, et al. Oxazolidinones inhibit cellular proliferation via inhibition of mitochondrial protein synthesis. Antimicrob Agents Chemother 2005;49:3896-902.
11. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
12. Matassova NB, Rodnina MV, Endermann R, et al. Ribosomal RNA is the target for oxazolidinones, a novel class of translational inhibitors. RNA 1999;5:939-46.
13. Xiong L, Kloss P, Douthwaite S, et al. Oxazolidinone resistance mutations in 23S rRNA of Escherichia coli reveal the central region of domain V as the primary site of drug action. J Bacteriol 2000;182:5325-31.
14. Burk A, Douzery EJP, Springer MS. The secondary structure of mammalian mitochondrial 16S rRNA molecules: refinements based upon a comparative phylogenetic approach. J Mammal Evol 2002;9:225-43.
15. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
16. Martin JL, Brown CE, Matthews-Davis N, et al. Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis. Antimicrob Agents Chemother 1994;38:2743-9.
17. McComsey G, Lonergan JT. Mitochondrial dysfunction: patient monitoring and toxicity management. J Acquir Immune Defic Syndr 2004;37(Suppl 1):S30-4.
18. Blazes DL, Decker CF. Symptomatic hyperlactataemia precipitated by the addition of tetracycline to combination antiretroviral therapy. Lancet Infect Dis 2006;6:249-52.
19. Bernstein WB, Trotta RF, Rector JT, Tjaden JA, Barile AJ. Mechanisms for linezolid-induced anemia and thrombocytopenia. Ann Pharmacother 2003;37:517-20.
20. Gurtler N, Schmuziger N, Kim Y, et al. Audiologic testing and molecular analysis of 12S rRNA in patients receiving aminoglycosides. Laryngoscope 2005;115:640-4.
21. Amacher DE. Drug-associated mitochondrial toxicity and its detection. Cur Med Chem 2005;12:1829-38.